After disappointing Phase IIb results for avicursen in December, Percheron will adopt a three-pronged business strategy.
Oculis has reported that the Phase II ACUITY trial of OCS-05, in treating individuals with acute optic neuritis, met the primary endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback